论文部分内容阅读
目的分析不能手术Ⅲ期非小细胞肺癌同步与序贯放化疗的疗效及毒副反应。方法对生存资料完整的94例Ⅲ期非小细胞肺癌病例进行回顾性分析,其中同步组46例、序贯组48例。同步组:放疗及同步2周期化疗,治疗结束后巩固化疗2~3周期;序贯组:化疗2~4周期后放疗,放疗结束后行0~2周期化疗。放疗采用三维适形放疗DT60~74Gy/30~37F。结果同步组与序贯组有效率分别为73.9%及52.2%(P<0.05);中位生存时间分别为17.0个月及11.5个月;1、2、3年生存率分别为73.9%、41.3%、19.6%及43.8%、20.8%、4.2%(P<0.05)。同步组局部复发及远地转移率明显低于序贯组(P<0.05)。Ⅲ级以上血液毒性同步组高于序贯组,差异有统计学意义。结论对于不能手术Ⅲ期NSCLC,同步与序贯放化疗相比可以延长生存期,降低局部复发及远地转移率,毒副反应能耐受。
Objective To analyze the efficacy and toxicity of synchronous and sequential chemo-radiotherapy in patients with stage III non-small cell lung cancer. Methods We retrospectively analyzed 94 cases of stage III non-small cell lung cancer with complete survival data, including 46 cases in synchronous group and 48 cases in sequential group. Synchronous group: radiotherapy and synchronous 2 cycles of chemotherapy, after the end of treatment, consolidation chemotherapy for 2 to 3 cycles; sequential group: radiotherapy after 2 to 4 cycles of chemotherapy, and 0 to 2 cycles of chemotherapy after radiotherapy. Radiotherapy uses three-dimensional conformal radiotherapy DT60~74Gy/30~37F. Results The effective rates of synchronous group and sequential group were 73.9% and 52.2% respectively (P<0.05). The median survival time was 17.0 months and 11.5 months respectively. The 1-, 2-, and 3-year survival rates were 73.9% and 41.3 respectively. %, 19.6% and 43.8%, 20.8%, 4.2% (P<0.05). The rate of local recurrence and distant metastasis in the synchronous group was significantly lower than that in the sequential group (P<0.05). More than grade III blood toxicity synchronization group was higher than the sequential group, the difference was statistically significant. Conclusion For patients with stage III NSCLC who cannot undergo surgery, synchronous and sequential radiotherapy can prolong survival, reduce local recurrence and distant metastasis, and tolerate toxic and side effects.